UBS lowered the firm’s price target on Moderna (MRNA) to $108 from $140 and keeps a Buy rating on the shares following a model review.

With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that ...

AvidXchange (NASDAQ:AVDX – Free Report) had its target price cut by Wells Fargo & Company from $10.00 to $9.00 in a report issued on Monday, Benzinga reports. They currently have an equal weight ...

Q3 2024 Earnings Call Transcript October 23, 2024 Impinj, Inc. misses on earnings expectations. Reported EPS is $0.02136 EPS, ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/chunks/Article.DIOO7zyo.js ...

Sensex Today | Stock Market LIVE Updates | Equity markets fell for the third consecutive day on Wednesday, primarily driven ...

A small negative candle was formed on the daily chart at the new swing lows of 24,341 with minor upper and lower shadows.

Q2 2024 Earnings Conference Call October 23, 2024 9:00 PM ETCompany ParticipantsTeruaki Urago - General Manager, ...

(Reuters) - The incipient migration of clients from Credit Suisse to UBS should take about another 18 months, UBS CEO Sergio ...

Inflation, high interest rates and political instability made the wealthiest clients become more cautious with art purchases ...

UBS analyst Justin Forsythe maintained a Sell rating on Worldline (0QVI – Research Report) today and set a price target of €5.25. The ...

“I’m far from trying to predict what’s going to happen,” UBS chief Sergio P. Ermotti told Semafor’s Liz Hoffman, at the World ...